CA3176448A1 - Barcodable exchangeable peptide-mhc multimer libraries - Google Patents

Barcodable exchangeable peptide-mhc multimer libraries

Info

Publication number
CA3176448A1
CA3176448A1 CA3176448A CA3176448A CA3176448A1 CA 3176448 A1 CA3176448 A1 CA 3176448A1 CA 3176448 A CA3176448 A CA 3176448A CA 3176448 A CA3176448 A CA 3176448A CA 3176448 A1 CA3176448 A1 CA 3176448A1
Authority
CA
Canada
Prior art keywords
peptide
mhci
mhc
multimerization domain
conjugation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176448A
Other languages
English (en)
French (fr)
Inventor
Ohad YOSEFSON
Thomas Malia
Andrew Hamel
Joanna SWAIN
Benjamin ROSCOE
Mohammad RASHIDIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repertoire Immune Medicines Inc
Original Assignee
Repertoire Immune Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repertoire Immune Medicines Inc filed Critical Repertoire Immune Medicines Inc
Publication of CA3176448A1 publication Critical patent/CA3176448A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3176448A 2020-03-31 2021-03-31 Barcodable exchangeable peptide-mhc multimer libraries Pending CA3176448A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003177P 2020-03-31 2020-03-31
US63/003,177 2020-03-31
PCT/US2021/025167 WO2021202727A2 (en) 2020-03-31 2021-03-31 Barcodable exchangeable peptide-mhc multimer libraries

Publications (1)

Publication Number Publication Date
CA3176448A1 true CA3176448A1 (en) 2021-10-07

Family

ID=75660333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176448A Pending CA3176448A1 (en) 2020-03-31 2021-03-31 Barcodable exchangeable peptide-mhc multimer libraries

Country Status (8)

Country Link
US (1) US20230287394A1 (https=)
EP (1) EP4126923A2 (https=)
JP (1) JP7846628B2 (https=)
CN (1) CN115776987A (https=)
AU (1) AU2021248941A1 (https=)
CA (1) CA3176448A1 (https=)
IL (1) IL296789A (https=)
WO (1) WO2021202727A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114644706B (zh) * 2022-02-16 2024-04-09 国家纳米科学中心 基于DNA纳米技术的pMHC多聚体制备方法及其应用
AU2023314797A1 (en) 2022-07-29 2024-12-12 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
DE10247014A1 (de) * 2002-10-09 2004-04-22 Erfle, Volker, Prof. Priv.-Doz. Dr. MHC-Multimere
GB0226227D0 (en) * 2002-11-09 2002-12-18 Avidex Ltd Receptors
WO2005047902A1 (en) 2003-11-03 2005-05-26 Beckman Coulter, Inc. Solution-based methods for detecting mhc-binding peptides
GB2422834B8 (en) * 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
WO2006136763A1 (en) * 2005-06-20 2006-12-28 Medigene Limited Synthetic ligands of peptide-mhc complexes, or cd1-antigen complexes
GB2430256B (en) 2005-09-19 2008-06-25 Proimmune Ltd A method of screening MHC molecules
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
EP2558491B1 (en) 2010-04-13 2018-07-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
CN102296807B (zh) 2011-06-27 2013-06-05 中国葛洲坝集团股份有限公司 管、槽圆弧形混凝土底板轻便滑模
JP6364352B2 (ja) * 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
EP2952520A1 (en) * 2014-06-06 2015-12-09 Stichting Sanquin Bloedvoorziening Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides.
SG10202005892SA (en) * 2014-06-06 2020-07-29 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
WO2015200541A1 (en) 2014-06-24 2015-12-30 Bio-Rad Laboratories, Inc. Digital pcr barcoding
SG11202007686VA (en) * 2018-02-12 2020-09-29 10X Genomics Inc Methods characterizing multiple analytes from individual cells or cell populations
WO2019238939A1 (en) * 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes
US20220073908A1 (en) * 2019-01-04 2022-03-10 Repertoire Immune Medicines, Inc. Methods of producing high diversity peptide libraries and promoting protein folding

Also Published As

Publication number Publication date
IL296789A (en) 2022-11-01
EP4126923A2 (en) 2023-02-08
WO2021202727A2 (en) 2021-10-07
JP2023520412A (ja) 2023-05-17
JP7846628B2 (ja) 2026-04-15
US20230287394A1 (en) 2023-09-14
AU2021248941A1 (en) 2022-11-17
CN115776987A (zh) 2023-03-10
WO2021202727A3 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US20230265157A1 (en) Mhc multimer expression constructs and uses thereof
US11668705B2 (en) General detection and isolation of specific cells by binding of labeled molecules
US20230287394A1 (en) Barcodable exchangeable peptide-mhc multimer libraries
US20220162695A1 (en) Use of dextramer in single cell analysis
US20220033460A1 (en) Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
US20110236411A1 (en) MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics
US20100226854A1 (en) MHC Peptide Complexes and Uses Thereof in Infectious Diseases
US20220088135A1 (en) Methods of making and using soluble mhc molecules
US20220090297A1 (en) Peptide libraries and methods of use thereof
WO2022026921A1 (en) Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
WO2022087154A1 (en) Mhc class ii peptide multimers and uses thereof
US20240076356A1 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
US20200347103A1 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
HK40095794A (en) General detection and isolation of specific cells by binding of labeled molecules
CN118355277A (zh) 评定mhc-肽-tcr相互作用和动力学的细胞测定和方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250415

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250516

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250516

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250819

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251022

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260327

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260327

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260420